Pharma Market Archives - Business Intelligence

Tag: Pharma Market

Pharmaceutical manufacturing

Winning in Emerging Markets: What Big Pharma Companies Must Do

Emerging markets are highly promising and offer a plethora of opportunities for pharmaceutical companies. As a result, there is an unprecedented increase in the number of companies in the life sciences industry that are turning to emerging markets such as Brazil, India, and China to set up their businesses. Pharma industry experts at Infiniti Research believe that big pharma companies that are innovative and advanced in terms of manufacturing, logistics and distribution, and understanding customer needs are more likely to gain an edge over the others in these coveted markets. Despite several efforts, some big pharma companies often fail to gain a major foothold in these regions. This issue occurs due to several reasons. Sometimes, new entrants in the big pharma market discover that operating and selling in emerging markets can be challenging due to market access requirements including manufacturing, logistics, and supply chain can be complex. Furthermore, unfavorable regulatory environment, dynamic pricing and reimbursement practices, and talent management challenges also pose major challenges for big pharma companies in emerging markets.

In this article, Pharma industry experts at Infiniti Research share some of the key strategies that big pharma companies can use to succeed in new and emerging markets.

Growth strategies for big pharma companies are increasingly dependent on expansion into emerging markets. Request a free proposal to know how we can help support your market expansion plan into emerging markets.

How big pharma can compete effectively in emerging markets

Big pharma companiesOne of the primary steps in establishing and executing a growth strategy for big pharma companies involve identifying commonalities across markets. These commonalities must support cost-effective approaches while taking into account the unique regulatory constraints and consumer attributes of different regions. Here are three key approaches for big pharma companies to capitalize on attractive opportunities in emerging markets.

Group customers into clusters

Customer submarkets in emerging countries can be identified within a national or regional market by analyzing and grouping consumers who have common health needs. Creating customer clusters in emerging markets will help big pharma companies to identify various customer challenges in the market and create tailored solutions to cater to the needs of these groups.

Identify cross-border commonalities

Constricting emerging market entry to national boundaries is a common mistake that big pharma companies make. An approach that is too focused on national or regional boundaries could mean that customer similarities across markets are not being sufficiently leveraged to create solutions that can move across borders. Identifying cross-border insights can enable big pharma companies to serve groups or clusters of customers more effectively and efficiently.

Timely and cost-effective execution

Given the fact that most life sciences companies operate in functional silos, executing solutions across markets in a timely and cost-effective manner could prove challenging. Therefore, big pharma companies must focus on creating a single, coherent strategy rather than trying to coordinate separate strategies. Two capabilities that are especially critical when planning the rapid execution of an emerging-market strategy include developing the ability to understand and to get close to the customer and improving the risk management capabilities.

Learn more about Infiniti’s solutions for big pharma companies

Pharma logistics

Identifying Critical Pharma Logistics Challenges in Canada

Every business endures pressure in terms of strict delivery schedules and meeting production efficiency. But when it comes to pharmaceuticals and healthcare product manufacturers, these deadlines become a matter of life and death, due to which ensuring product quality and timely deliveries are paramount for companies operating in this sector. This necessitates them to incorporate a changeover from existing pharma logistics strategies and traditional supply chain practices to new and innovative techniques to improve efficiency. Furthermore, in order to be adequately equipped to distribute pharmaceutical and healthcare products across Canada, pharma companies must be fully aware of the pharma logistics pain-points that the market has to offer.

As research and technology continue to fundamentally transform pharma capabilities, pharma logistics is being forced to adapt to changes in the types of products brought to the market. Request a free proposal to know how our experts can help you adapt to the changing trends in the pharma industry.

Large territories

Cold chains used for pharma logistics in Canada need to be highly robust due to the region’s vast territories. The region’s immense landscape provides challenging driving conditions including long distances, mountain winter conditions in the west, and unexpected weather scenarios that can result in roadblocks to effective delivery such as bridges ruined by rain, roads blocked by ice, and many other hazards. All of these factors have the potential to not only add to major transit delays but can also result in significant costs. Moreover, it can also prove to be difficult for pharma logistics providers to reach places up in the north due to limited infrastructure. In such territories, it may not be possible to place the pharmaceutical products on a direct flight to the required location, so the medicine may need to travel via truck for two days to complete the journey safely.

Extreme weather conditions

Temperatures can sometimes soar to extremes in Canada and this can sometimes compromise the quality of pharma products during transit. The pharma logistics facilities used must be able to protect the products from overheating in the hot climates or from freezing in the cold climates. This places a heavy burden on validating quality systems within the chain. The unpredictability of the weather conditions in Canada, in terms of their severity and duration, makes it extremely challenging for pharma logistics providers to preserve and ensure the quality and timely delivery of products.

Few industries face the scrutiny and demand for excellence as those engaged in pharma manufacturing. Get in touch with us to know more about our solutions for pharma companies and learn how we can help you stay in line with the advancements in the pharmaceutical industry.

Partnerships and collaborations

The pharmaceutical industry in Canada is rapidly moving towards an externalized R&D set up through partnerships and collaborations. A similar trend has been noted in the pharma logistics segment with several manufacturers outsourcing supply chain processes in an effort to benefit from the expertise of pharma logistics providers. However, this comes with challenges of its own. By delegating responsibilities externally, pharma manufacturers risk losing the end-to-end control that they once had on all their operations. Therefore, a stringent and robust quality agreement must be formed between all parties to protect the integrity of the product. Particularly well-defined standard operating procedures must be established regarding how the product and the raw materials will be treated. Cold chain partnerships with pharma logistics companies are largely a matter of trust. Once the cargo is handed to a forwarder or carrier, shippers must rely on their partners to safely steward their temperature-sensitive products through the cold chain. The success of these partnerships relies on effective communication. The best way to ensure effective monitoring of shipments is a truly collaborative approach, whereby all stakeholders charged with moving temperature-sensitive cargo work together to develop and implement the required programs.

Parallel Trade

The recent spate of selling pharmaceuticals from Canada into the US is only the tip of the iceberg. Canadian pharmaceutical companies were buying drugs at a lower price negotiated by the Canadian government and selling them across the border into the US where pricing is higher. This also occurs between borders in Europe between large wholesalers, as well as through black market transactions in developing countries. The danger here is that pharmaceutical companies lose the ability to know where these drugs are coming from. This can be largely avoided by the use of RFID technology.

Learn how you can enhance your pharma logistics capabilities.

Recent Posts

pharmaceutical industry

Illuminating the impact of Brexit on Europe’s Pharmaceutical industry

Pharmaceutical industry products are in the list of top five products that are most imported and exported from the UK to the EU and vice versa.

Brexit can have several implications of Europe’s pharmaceutical industry. From product development to market approval to the shipping of medicines and medical devices, pharmaceutical companies can expect to be affected in a broad range of areas. Companies in the pharmaceutical industry in the UK will have to manage the impact of Brexit carefully to prevent some of the negative aspects. However, uncertainty will have adverse effects on pharmaceutical and life sciences companies in other European countries as well. Experts at Infiniti predict how Brexit will affect life science and pharmaceutical industry.

Rising demand for personalized treatments, an ageing population, and the rise of new manufacturing technologies are some of the primary growth opportunities for the UK pharmaceutical sector. Request a free proposal to know how our solutions can help you stay prepared to cope with the market trends and changes.

Relocating European Medicines Agency (EMA)

One of the key pharmaceutical industry market access challenges that Brexit brings along with it, irrespective of the path it takes is related to the future location of the European medicines agency. Since its inception in 1995, EMA had been located in London. However, the Netherlands has now won the bid to host new EMA headquarters post-Brexit. With the EMA headquarters soon moving to Amsterdam, they may implement several changes to rules for medicinal products that are developed and tested in the UK. However, the extent of Brexit-induced changes to the pharmaceutical industry has yet to be decided.

Movement of people and pharma products

Pharma products form a considerable part of goods that are exported to and from the UK. Any post-Brexit hurdles to the free movement of goods could mean trouble for those supplies, potentially leading to temporary drug shortages. This is especially true in the case of drugs such as medicinal insulin that are not manufactured in the UK nor is it easily stored, as it requires temperature-controlled conditions. In order to reduce the risk of drug shortages in the case of a no-deal Brexit, the British government has asked pharmaceutical companies to add a minimum of six weeks’ worth of additional backup supply of medicines to their usual buffer stocks by the exit date, and to ensure that contingency plans were in place for drugs with shorter shelf lives. However, it is not only the movement of medicines that’s at risk. As the possibility of stricter rules regarding the flow of people between the UK and the EU looms, companies in the pharmaceutical industry are concerned about their ability to attract talent from outside Britain in the future. It is vital that pharmaceutical companies to still be able to access the best talent from around the world.

Emerging markets represent an exceptional opportunity for the pharmaceutical sector. Get in touch with our experts for more insights on how to capture the true value of the pharmaceutical market.

Change in the UK’s contribution to drug regulation

UK plays a major role in drug regulation in the EU through the work of the Medicines and Healthcare Products Regulatory Agency (MHRA). The UK frequently serves as rapporteur/co-rapporteur in the EU’s centralized procedure and as the reference member state in the decentralized procedure. It will prove to be a challenging task to replace the MHRA’s capacity and expertise, particularly if the timetable for reform is aggressive.

 

Safe supply of blood and organs

Another pressing challenge faced by companies in the pharmaceutical industry due to Brexit is linked to ensuring blood and blood products are safe. If there is a no-deal Brexit, the EU Blood Directives will not apply to the UK and it will be considered a third country by the EU regarding sharing blood, blood components, and information. The UK Government has declared that in the event of a no-deal, the current blood safety and quality standards for blood and blood components will remain the same, and therefore adhere to EU standards, allowing them to be imported into the EU. Similarly, the UK Government has laid out its provisions for ensuring the supply, as well as the safety and quality, of organs, tissues, and cells in the event of a no-deal. The UK would no longer be part of the EU Organ and EU Tissues and Cells directives, however, relevant UK establishments, such as stem cell laboratories and fertility clinics, would be required to work to the same standards. These organizations would need to individually agree on import and export of the products with EU and EEA authorities and establishments.

Learn more about Infiniti’s solutions for the pharmaceutical industry.

Recent Posts

new product launch

Attaining New Product Launch Success in the Pharma Industry

A new product launch is one of the biggest expenses incurred by pharma companies worldwide. The right product launch strategy can help ensure that the product is recognized and accepted by physicians, KOL, and patients alike. Pharma companies invest considerable time and money into drug development and clinical trials. In case a new product launch plan does not give the desired results, the burden becomes too heavy on pharmaceutical companies. While the level of clinical differentiation plays an important role in guaranteeing a drug’s success, there are many examples of successful drugs that were not considered a major clinical breakthrough during the product launch. Here are some tried and tested strategies for companies in the pharma industry to improve a new product launch.

A new product launch strategy in the pharma industry today requires greater coordination across the entire organization, including market access, patient services, medical affairs, regulatory, marketing, and sales. Request a free proposal to know how our solutions can help you ensure a successful and smooth new product launch.

New Product Launch Strategies for Pharma Companies

new product launchGo beyond clinical trial results

Today, new product launches in the pharma industry face unprecedented intensity in terms of competition. The average window of time in which a drug remains in the market before competitor products arrive has dropped down from approximately eight years to less than five years. This onslaught of new drugs makes it highly challenging for pharma companies to use phase III clinical trial data alone to differentiate their drug in front of physicians, health insurers, and regulators. Companies can ensure success in the case of a new product launch only if they are adept in communicating both the clinical and non-clinical benefits of a new product to physicians and decision-makers.

Focus on timing

Timing is critical to the success of any new product launch. Pharma companies need to plan and be prepared months ahead of the actual new product launch date. As the launch date gets closer, companies can initiate discussions on social media platforms and forums on the disease that is being targeted. Even after the new product launch, provide actionable content using those exact same channels. Provide scientifically accurate information on how your new product aids in combating the targeted disease and enhancing patient outcomes.

Pharma companies that repeatedly outperform expectations for a new product launch develops new sources of differentiation, focus on building superior customer experiences, and treat drug launches as a micro-battle. Get in touch with our experts to know how our solutions can help you get there.

Build customer advocacy

Physicians generally tend to consider a much wider set of clinical data before prescribing a drug. This includes clinical protocols, drug pricing, and the type of patient to whom the drug should be prescribed, and the treatment regimen involved. According to pharma industry experts at Infiniti, brand preference of most physicians are attributed to customer experience factors beyond the product.This includes factors such as how well pharma companies support physicians by providing answers to medical questions, identifying patients, and connecting physicians with peers.

Learn more about Infiniti’s solutions for companies in the pharma industry

Trends in pharmaceutical industry

Analyzing the Market Innovations and Trends in Pharmaceutical Industry in the United States | Infiniti Research

Analyzing Trends in Pharmaceutical Industry

Rising healthcare costs and economic uncertainties have put US pharmaceutical companies in a state of turmoil. However, on the brighter side, with biosimilars gaining popularity and new drug pricing and reimbursement approaches, pharmaceutical companies will witness rapid transformations over the coming year. Hence, pharma companies are under the pressure to stay abreast with the latest market innovations and trends in pharmaceutical industry. This is where companies realize the need to leverage market trend analysis solution.

Want to know the latest trends in pharmaceutical industry and keep pace with the market innovations? Our market trend analysis can help. Request a FREE proposal today!

Business Challenge

The client is a Canadian pharmaceutical company. The client was looking to expand their operations to the United States. With rapid transformations happening in the US pharma market, the client wanted to identify the trends in pharmaceutical industry and keep pace with the market innovations. The client, therefore, partnered with Infiniti Research to leverage their expertise in offering market trend analysis solution.

Furthermore, the client wanted to:

Analyze the market potential

By analyzing the trends in pharmaceutical industry and understanding the market innovations, the client wanted to understand the market potential for their product and services in the United States.

Understand technological trends in pharmaceutical industry

With the industry-wide proliferation of cloud technologies and artificial applications (AI) driving pharmaceutical industry growth, the client wanted to analyze all the technological trends in pharmaceutical industry in the United States.

Understand rising demand for biosimilars

With biosimilars gaining popularity in the US pharmaceutical market and providing cost savings for payers and patients, the client wanted to analyze how biosimilars are changing the US pharma market.

Analyze rising drug pricing

With the US government tightening up conditions for drug pricing and related instruments such as rebates and discounts, the client wanted to analyze the trends in pharmaceutical industry related to drug pricing.

Analyzing the latest trends in pharmaceutical industry is becoming vital for pharma companies that are looking to enter a new market or expand their business operations. CONTACT US to know how our market trend analysis can help you understand the latest market innovations and adapt to unexpected market fluctuations.

Solutions Offered

As a part of the trend analysis engagement, the experts at Infiniti Research conducted a thorough US pharmaceutical industry analysis and market sizing analysis. This phase of the trend analysis engagement helped the client to understand the recent market developments and estimate the market potential for their products and services. Also, the client was able to identify the market size of pharmaceutical industry in the US.

The experts also leveraged product research engagement to help the client analyze the complete product development lifecycle, trade-offs, and gain insights on product-specific revenues to boost the value proposition.  Furthermore, the experts analyzed technological trends in pharmaceutical industry and monitored how the client’s major competitors employed the latest technological trends in their business processes.

Furthermore, by leveraging Infiniti’s expertise in conducting industry trend analysis engagement, the experts helped the client to understand how biosimilars are transforming the US pharma industry and analyzed how top US pharma companies are spending on biosimilars.

By leveraging Infiniti’s expertise in offering market opportunity analysis, the experts also helped the client to review potential barriers to market entry and assess markets’ readiness for their product and service offerings.

Results Obtained

With Infiniti’s market trend analysis engagement, the client was able to efficiently analyze the trends in pharmaceutical industry and stay abreast with market innovations. Also, tracking emerging trends in pharmaceutical industry and assessing the regional market developments helped the client to devise a market entry plan to enter the US pharma market. Furthermore, within two years of entering the new market, the client was able to achieve a leading edge in the US pharma market and become one among the top 20 pharma companies in the United States.

Trends in Pharmaceutical Industry

pharma industry trends

Request for more information to learn other benefits of keeping pace with pharma market innovation and analyzing pharmaceutical industry trends.

Competitor analysis

Top Manufacturing Trends Flourishing in the Pharma Industry

The global economic uncertainties, increasing healthcare costs and expiring patents are putting pharma companies in a state of turmoil. However, on the brighter side, the rapid development of the emerging markets, progress in drug research, the rise in generics production, the availability of high-potency drugs, and innovations in manufacturing trends will sustainably modify the global pharmaceutical landscape. Moreover, the increasing prevalence of chronic diseases and the growing demand for medications, high market growth, new medicines, and therapy forms, changing regulations, and progressing digitization are going to give birth to new manufacturing trends to meet the growing demand.

Manufacturing trends in the pharma industry

Process analytical technology

This initiative sets a legal framework in the USA aiming to motivate pharma companies to improve the production process and achieve consistent quality while reducing waste and costs. In order to comply with this regulation and the changing manufacturing trends, pharma companies need to have systems in place that ensure detailed monitoring of their continuous and batch processes. Process analytical technology is one of the vital manufacturing trends that enables and drives continuous manufacturing. It was identified as one of the most important manufacturing trends in pharma companies along with integrated manufacturing business and automation processes.

banner IR

Digitization and labeling information

Effective tracking, tracing, and labeling is a mandatory proof of authenticity and prevention of drug counterfeiting. Digitization of labeling information has resulted in greater emphasis being placed on collecting, securing, and processing digital data about pharma products.

Low-volume drugs

There are several issues relating to introducing new drugs in the market. This includes manufacturing issues as well, so a review of manufacturing trends in approvals of new molecular entities (NMEs) can provide insight into manufacturing activity. A key trend in NME approvals is the increased share of orphan drugs approved as NMEs. Orphan drugs are defined as drugs that treat diseases which are known to affect 200,000 or fewer people, as defined by the US Food and Drug Administration (FDA). The FDA provides incentives, including market-exclusivity benefits, for developing orphan drugs. Due to a smaller patient population, these drugs are typically produced in lower volumes when compared to primary care drugs.Get More Info

Risk-based manufacturing inspections

The FDA is continuing its plan to use a risk-based selection model for manufacturing inspections in the pharma industry. This forms a part of its strategy to allocate resources more effectively and gain greater parity between inspections of domestic and foreign drug-manufacturing facilities. During September 2018), the FDA published an internal policy that outlines the agency’s risk-based, site-selection model for inspecting foreign drug-manufacturing facilities. The FDA prioritizes inspections of sites regardless of their location with the help of a risk-based site-selection model. This is one of the critical manufacturing trends that pharma companies must watch out for.


Gain more insights into how Infiniti’s solutions can help pharma companies

Contact US

Market Opportunity Assessment for a Leading Pharma Market Client

The recently unfolded challenges have drastically changed the pharma landscape leading to drug approval stagnation and diminished R&D productivity.

The pharma market is well-known for innovation- new and advanced pharmaceutical drugs are incessantly being discovered and marketed across the globe. In addition, mergers and acquisitions are taking place on a regular basis and new studies are being conducted regularly by the pharmaceutical drugs manufacturing companies to enhance their product portfolio.

In addition, the rapidly changing technical landscape has leveraged the shift toward a more patient-centric healthcare, as evidenced by telemedicine and wearable biometric devices. However, patient-centric care has proven to be rewarding as well as challenging for pharma companies. Even with the recently unfolded challenges changing the pharma landscape, there are promising opportunities on the horizon with patient-centric healthcare trends and biosimilars that are likely to accelerate market growth.

The Business Challenge

  • The client: A pharmaceutical drugs manufacturing company

To identify and quantify the opportunities in the pharma market, the client – a leading pharmaceutical drugs manufacturing company – approached Infiniti to conduct a market opportunity assessment. The client wanted to identify and gauge the attractiveness of business opportunities in the pharma market. Lack of visibility regarding market conditions posed a major challenge for the client as they were unable to define a clear business strategy and justify their actions. Therefore, their primary objective was to identify new opportunities by determining the market factors affecting their business growth.

How Can Market Opportunity Assessment Help Pharmaceutical Drugs Manufacturing Companies?

Understanding and gaining detailed insights into market opportunities is essential for any organization A detailed market opportunity assessment acts as a cornerstone of a successful business strategy and also helps identify new market opportunities. However, it doesn’t necessarily require huge investments in terms of time and energy. By investing in market opportunity assessment, pharmaceutical drugs manufacturer can create a basic framework necessary for- making data-driven decisions, resource optimization, and increase brand perception.


Summary of our market opportunity assessment

Pharma Market

Ask An Analyst


Client Journey

Infiniti’s market opportunity assessment helped the pharma market client gain a detailed industry outlook. It also helped the client identify major market opportunities along with the trends and implications for each opportunity.

Furthermore, to help the client assess the competitive landscape and identify imminent market trends, the market experts at Infiniti conducted a detailed market opportunity assessment to determine customer needs and accordingly deliver the products to enhance customer satisfaction. The approach included primary and secondary research methodologies coupled with qualitative and quantitative data collection procedures. The experts also reached out to various stakeholders in the pharma market.

Solution Benefits and the Business Impact

Infiniti’s market research experts helped the pharmaceutical drugs manufacturing company accomplish their organizational objectives, leading to an increase in market share. The market opportunity assessment also helped the client keep tabs on market opportunities to enhance their product and services offerings. Moreover, the solutions offered helped in expanding their business in existing as well as new markets.

The Future

With the rapid growth in the pharma market, it might be difficult for pharmaceutical drugs manufacturers to gauge the attractiveness of market opportunities. In order to withstand the growing competitive pressure, leading players in the pharma market are increasingly investing in other alternatives such as – industry partnerships, capacity expansions, market opportunity assessments, and mergers and acquisitions.


A must-read case study for strategy specialists and decision makers looking to develop an understanding of the global pharma market.

Request Proposal


Related Posts:

Close
Infiti Logo

Hello there!

Contact us to know more about our cost-effective custom market research offerings to support efficient market penetration, new product launch, and devise strategies to monitor and outperform your competitors.

Cookie Policy

The Site uses cookies to record users' preferences in relation to the functionality of accessibility. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice